Market closed
Veracyte/$VCYT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Veracyte
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
Ticker
$VCYT
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
824
Website
Veracyte Metrics
BasicAdvanced
$2.3B
95.84
$0.31
1.80
-
Price and volume
Market cap
$2.3B
Beta
1.8
52-week high
$47.32
52-week low
$19.71
Average daily volume
980K
Financial strength
Current ratio
4.734
Quick ratio
4.273
Long term debt to equity
3.677
Total debt to equity
4.314
Interest coverage (TTM)
13,388.50%
Management effectiveness
Return on assets (TTM)
1.32%
Return on equity (TTM)
2.17%
Valuation
Price to earnings (TTM)
95.839
Price to revenue (TTM)
5.098
Price to book
1.96
Price to tangible book (TTM)
7.03
Price to free cash flow (TTM)
35.612
Growth
Revenue change (TTM)
23.46%
Earnings per share change (TTM)
-130.27%
3-year revenue growth (CAGR)
26.63%
3-year earnings per share growth (CAGR)
-34.69%
What the Analysts think about Veracyte
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Veracyte stock.
Veracyte Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Veracyte Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Veracyte News
AllArticlesVideos
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
Business Wire·1 week ago
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
Business Wire·1 month ago
Veracyte, Inc. (VCYT) Q4 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Veracyte stock?
Veracyte (VCYT) has a market cap of $2.3B as of May 03, 2025.
What is the P/E ratio for Veracyte stock?
The price to earnings (P/E) ratio for Veracyte (VCYT) stock is 95.84 as of May 03, 2025.
Does Veracyte stock pay dividends?
No, Veracyte (VCYT) stock does not pay dividends to its shareholders as of May 03, 2025.
When is the next Veracyte dividend payment date?
Veracyte (VCYT) stock does not pay dividends to its shareholders.
What is the beta indicator for Veracyte?
Veracyte (VCYT) has a beta rating of 1.8. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.